Qualitative alterations in urinary 17-ketosteroid excretion during aminoglutethimide administration.
D015068:17-Ketosteroids / Q000652:urine*; D000308:Adrenocortical Hyperfunction / Q000150:complications; D000616:Aminoglutethimide / Q000627:therapeutic use; D000738:Androsterone / Q000652:urine*; D000814:Aniline Compounds / Q000627:therapeutic use*; D000927:Anticonvulsants / Q000627:therapeutic use*; D002624:Chemistry, Clinical; D002986:Clinical Trials as Topic; D003480:Cushing Syndrome / Q000188:drug therapy / Q000652:urine; D003687:Dehydroepiandrosterone / Q000652:urine*; D005043:Etiocholanolone / Q000652:urine*; D005938:Glucocorticoids / Q000652:urine*; D006801:Humans; D006965:Hyperplasia; D007006:Hypogonadism / Q000188:drug therapy / Q000652:urine; D011728:Pyridones / Q000627:therapeutic use*; D013739:Testosterone / Q000627:therapeutic use
D015068:17-Ketosteroids; D000814:Aniline Compounds; D000927:Anticonvulsants; D005938:Glucocorticoids; D011728:Pyridones; D000616:Aminoglutethimide; D013739:Testosterone; D003687:Dehydroepiandrosterone; D005043:Etiocholanolone; D000738:Androsterone